Core Viewpoint - CorMedix Inc. has announced a public offering of 6,604,507 shares of common stock, expected to generate approximately $85 million in gross proceeds, with a closing date anticipated around June 30, 2025, subject to customary conditions [1][3]. Group 1: Offering Details - The offering consists of 6,604,507 shares of common stock, with total gross proceeds expected to be around $85 million [1]. - Underwriters have a 30-day option to purchase up to an additional 15% of the shares offered [1]. - RBC Capital Markets is the sole bookrunner for the offering, with Truist Securities, Citizens Capital Markets, and Needham & Company serving as capital markets advisors [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, which may include working capital, research and development expenses, and potential strategic transactions such as acquisitions or collaborations [3]. Group 3: Company Background - CorMedix Inc. is focused on developing and commercializing therapeutic products for life-threatening diseases, with its lead product DefenCath approved by the FDA on November 15, 2023 [7]. - DefenCath was commercially launched in inpatient settings in April 2024 and in outpatient settings in July 2024 [7]. - The company plans to commence clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and aims to develop DefenCath for additional uses [7].